IRVINE, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals announced today that Rajesh Shrotriya, M.D., Chairman, President and CEO of Spectrum, will present an overview of the Company on Tuesday, February 13, 2007 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time), at the BIO CEO & Investor Conference, being held at the Waldorf Astoria in New York City. Spectrum's presentation will be held in the Conrad Suite.
A live webcast of Spectrum's presentation will be available under the investor relations section of its corporate website, http://www.spectrumpharm.com. Replays of the presentation will be available for 30 days following the event. Please connect to Spectrum's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals acquires, develops and commercializes a diversified portfolio of drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum's expertise lies in identifying undervalued drugs with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most viable and low-risk methods of commercialization. The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease. For more information, please visit http://www.spectrumpharm.com.
Forward-looking Statements -- This press release may contain forward- looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire and develop its portfolio of drug candidates, the Company's pipeline, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that past results may not be indicative of future results, the possibility that price and other competitive pressures may make the marketing and sale of our generic drugs not commercially feasible, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of significant revenues, our limited human and financial resources, our limited experience in establishing strategic alliances, our limited marketing experience, our limited experience with the generic drug industry, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
COMPANY CONTACTS Raj Shrotriya President & CEO rshrotriya@spectrumpharm.com 949-788-6700 x 295 Russell Skibsted Chief Business Officer rskibsted@spectrumpharm.com 949-788-6700 x 234 Paul Arndt Manager, Investor Relations parndt@spectrumpharm.com 949-788-6700 x 216
Spectrum PharmaceuticalsCONTACT: Raj Shrotriya, President & CEO, ext. 295,rshrotriya@spectrumpharm.com, or Russell Skibsted, Chief Business Officer,ext. 234, rskibsted@spectrumpharm.com, or Paul Arndt, Manager, InvestorRelations, ext. 216, parndt@spectrumpharm.com, all of SpectrumPharmaceuticals, +1-949-788-6700
Web site: http://www.spectrumpharm.com/
